OPRD1 Protein
OPRD1
Origin: Human
Host: Mammalian Cells
Synthetic Nanodisc
-
- Target See all OPRD1 products
- OPRD1 (Opioid Receptor, delta 1 (OPRD1))
- Protein Type
- Synthetic Nanodisc
-
Origin
- Human
-
Source
- Mammalian Cells
- Purpose
- Human OPRD full length protein-synthetic nanodisc
- Characteristics
- Unlike other membrane scaffold protein (MSP) Nanodisc on the market, our synthetic Nanodisc can be prepared directly from the cells. The polymers used during this process have a dual function. It dissolves the cell membranes, like the detergent, and uses cellular phospholipids to form Nanodisc around the membrane proteins. The target protein embedded Nanodiscs can then be purified.
-
-
- Comment
-
Advantages of Synthetic Nanodiscs:
- Highly purified membrane proteins
- High solubility in aqueous solutions
- High stability
- Proteins are in a native membrane environment and remain biologically active
- No detergent and can be used for cell-based assays
- No MSP backbone proteins
- Intolerant to acids and high concentrations of divalent metal ions
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5 % - 8 % trehalose is added as protectants before lyophilization.
- Storage
- -20 °C,-80 °C
- Storage Comment
- Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
- Expiry Date
- 12 months
-
- Target
- OPRD1 (Opioid Receptor, delta 1 (OPRD1))
- Alternative Name
- OPRD (OPRD1 Products)
- Synonyms
- OPRD Protein, DOR-1 Protein, Nbor Protein, mDOR Protein, opioid receptor delta 1 Protein, opioid receptor, delta 1 Protein, OPRD1 Protein, Oprd1 Protein
- Background
- G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.[UniProtKB/Swiss-Prot Function]
- Molecular Weight
- The human full length OPRD protein has a MW of 40.4kDa
- UniProt
- P41143
- Pathways
- Protein targeting to Nucleus
-
You are here:
